睿知中国疾病研究地图
候选清单0

桂林桂林医学院

桂林医学院附属医院

Affiliated Hospital of Guilin Medical University

在本站收录的 53 种疾病中,这家医院列在其中 12 种下,依据是它牵头的研究论文,以及它作为牵头方或研究中心登记的试验。

这里展示的是公开记录中的研究活动,不是医疗水平评级。能否为某位患者提供帮助,应由医院和主治医生判断。

这家医院的官网还没有核对。

联系这家医院

桂林医学院附属医院的研究

选择一种疾病,查看背后的论文和试验。 每个方块显示 2021–2025 年牵头的论文数和每年的数量。

只包括本站收录的 53 种疾病。未列出某种疾病,表示在这些记录中这家医院没有达到该病的列出标准,不代表它不诊治该病。 哪些医院会被列出

  1. 鼻咽癌Nasopharyngeal carcinoma35 篇牵头论文
  2. 肝细胞癌Hepatocellular carcinoma66 篇牵头论文牵头 1 项开放试验
  3. 脊索瘤Chordoma1 篇牵头论文
  4. 骨肉瘤Osteosarcoma3 篇牵头论文
  5. 神经母细胞瘤Neuroblastoma3 篇牵头论文
  6. 尤文肉瘤Ewing sarcoma0 篇牵头论文
  7. 多发性骨髓瘤Multiple myeloma3 篇牵头论文牵头 1 项开放试验
  8. β 地中海贫血Beta thalassaemia3 篇牵头论文
  9. 肝包虫病Hepatic echinococcosis2 篇牵头论文
  10. 特发性肺纤维化Idiopathic pulmonary fibrosis1 篇牵头论文
  11. 白塞病Behçet disease0 篇牵头论文
  12. IgA 肾病IgA nephropathy1 篇牵头论文

未列出的收录疾病:食管鳞状细胞癌、胃癌、肝母细胞瘤、视网膜母细胞瘤、胃肠道间质瘤、B 细胞急性淋巴细胞白血病、再生障碍性贫血、噬血细胞性淋巴组织细胞增生症、血友病 A、非典型溶血性尿毒症综合征、血栓性血小板减少性紫癜、范可尼贫血、视神经脊髓炎谱系疾病、IgG4相关性疾病、重症肌无力、烟雾病、肝豆状核变性、胆道闭锁、抗 NMDA 受体脑炎、大动脉炎、肺淋巴管平滑肌瘤病、肌萎缩侧索硬化症、脊髓性肌萎缩症、法布雷病、庞贝病、杜氏肌营养不良、Alport 综合征、戈谢病、尼曼-匹克病 C 型、成骨不全症、原发性胆汁性胆管炎、原发性硬化性胆管炎、先天性膈疝、先天性巨结肠、遗传性大疱性表皮松解症、遗传性血管性水肿、家族性腺瘤性息肉病、Leber 遗传性视神经病变、Majeed 综合征、NGLY1 缺乏症、ISG15 缺乏症。

癌症

鼻咽癌

Nasopharyngeal carcinoma

2021–2025 年中国大陆作者发表的 2,375 篇鼻咽癌 PubMed 英文论文中,这家医院牵头了 35 篇,占 1.5%。

牵头论文
35
2021–2025 年
牵头试验
1
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
6
由其他机构牵头
每年牵头的论文数
2021: 7720212022: 6620222023: 6620232024: 8820242025: 772025

桂林有 2 家医院列在鼻咽癌下全国有 176 家医院列在鼻咽癌下

这家医院参与的开放试验 6

依据 ClinicalTrials.gov 在 2026年11月8日 的登记,包括正在招募、即将招募和邀请入组。仅在中国临床试验注册中心(ChiCTR)登记的试验不在其中。能否参加由研究团队决定。

  1. 正在招募
    A Study of YL201 in Combination With Toripalimab and With or Without Cisplatin in Nasopharyngeal Carcinoma.
    分期
    I/II期
    开始
    2025-11
    登记号
    NCT07258979

    年龄 18 岁 至 75 岁(登记的条件)

    牵头方不是列出的医院;另有 19 家列出的医院为研究中心上海、东莞、南宁、南昌、厦门、广州、成都、昆明、杭州、桂林、江门、海口、福州、重庆、长沙、韶关

  2. 正在招募
    Effect of Immunonutrients on Oral Mucositis in Nasopharyngeal Carcinoma Patients After Chemoradiotherapy
    分期
    不分期
    开始
    2023-06
    登记号
    NCT05892354

    年龄 18 岁 至 70 岁(登记的条件)

    牵头:广西医科大学第一附属医院;另有 13 家列出的医院为研究中心南宁、南昌、广州、杭州、柳州、桂林、梧州、海口、福州

  3. 正在招募
    Induction Chemotherapy Followed by IMRT or Concurrent Chemoradiotherapy in Locoregionally Advanced Nasopharyngeal Carcinoma
    分期
    III期
    开始
    2022-11
    登记号
    NCT05527470

    年龄 18 岁 至 65 岁(登记的条件)

    牵头方不是列出的医院;另有 2 家列出的医院为研究中心桂林、梧州

  4. 正在招募
    Concurrent and Adjuvant Nimotuzumab Combined With Induction Chemotherapy Plus Chemoradiation in Nasopharyngeal Carcinoma
    分期
    不分期
    开始
    2022-12
    登记号
    NCT05717790

    年龄 18 岁 至 70 岁(登记的条件)

    牵头:广西医科大学第四附属医院;另有 6 家列出的医院为研究中心中山、广州、柳州、桂林、梧州

  5. 即将招募
    Ivonescimab Combined With Chemoradiotherapy in High-Risk Locoregionally Advanced Nasopharyngeal Carcinoma
    分期
    II期
    开始
    2026-08
    登记号
    NCT07064902

    年龄 18 岁 至 65 岁(登记的条件)

    牵头:中山大学肿瘤防治中心;另有 2 家列出的医院为研究中心厦门、广州、桂林

  6. 即将招募
    Impacted Tooth Management and Osteoradionecrosis Risk in NPC
    分期
    不分期
    开始
    2026-08
    登记号
    NCT07764887

    年龄 18 岁 至 75 岁(登记的条件)

    牵头:广西医科大学第一附属医院;另有 6 家列出的医院为研究中心中山、南宁、柳州、桂林、梧州

在试验总页面查看

排列:先正在招募,再即将招募和邀请入组;同类按开始时间从新到旧。不是排名。

这些数字背后的记录
研究主题复发与转移放疗技术诱导/同步化疗
论文中的科室放疗科耳鼻喉/头颈外科影像/核医学科肿瘤内科
牵头的论文35
  1. Rhamnocitrin induces apoptosis of human nasopharyngeal carcinoma by inhibiting IGF-1R signaling pathway in vitro.2026Journal of Asian natural products research
  2. Integrative analysis of taurine metabolism-related genes prognostic signature with immunotherapy and identification of ABCB1 and GORASP1 as key genes in nasopharyngeal carcinoma.2025Amino acids免费全文
  3. YTHDF2 enhances proliferation and metastasis of nasopharyngeal carcinoma by mediating m6A modification in destabilizing FOXO1 mRNA.2025Cancer biology & therapy免费全文
  4. Efficacy and Safety of Vascular-Targeting Agents Plus Chemotherapy Versus Chemotherapy Alone in Recurrent or Metastatic Nasopharyngeal Carcinoma Patients: A Multicenter Clinical Cohort Study.2025Cancer control : journal of the Moffitt Cancer Center免费全文
  5. Influence of COVID-19 Vaccination on Treatment-Related Adverse Events and Oncologic Outcomes of Nonmetastatic Nasopharyngeal Carcinoma.2025Head & neck
  6. Combined application of BNLF2b antibody with VCA-IgA, Rta-IgG, and Zta-IgA in nasopharyngeal carcinoma screening in the Guangxi region.2025PloS one免费全文
  7. Anlotinib monotherapy in recurrent or metastatic nasopharyngeal carcinoma: a multicenter case-series analysis.2025Radiology and oncology免费全文
  8. Interrogating ABCC1 and CASP1 as key players in epigallocatechin gallate's action against radiotherapy-resistant nasopharyngeal carcinoma.2025Scientific reports免费全文
  9. Multi-Omics Exploration of the Mechanism of Curcumol to Reduce Invasion and Metastasis of Nasopharyngeal Carcinoma by Inhibiting NCL/EBNA1-Mediated UBE2C Upregulation.2024Biomolecules免费全文
  10. Progress of Angiogenesis Signal Pathway and Antiangiogenic Drugs in Nasopharyngeal Carcinoma.2024Current molecular pharmacology
  11. Chemotherapy, Radiation Therapy, and Nasopharyngeal Carcinoma-Reply.2024JAMA oncology
  12. Induction Chemotherapy Followed by Radiotherapy vs Chemoradiotherapy in Nasopharyngeal Carcinoma: A Randomized Clinical Trial.2024JAMA oncologyRCT免费全文
  13. An individualized immune prognostic signature in nasopharyngeal carcinoma.2024Oral oncology
  14. Development and validation of an individualized angiogenesis and tumor-infiltrating lymphocytes prognostic signature in nasopharyngeal carcinoma.2024Pathology, research and practice
  15. 18F-NaF uptake in skull-base bone as a predictor of treatment response in advanced nasopharyngeal carcinoma.2024Scientific reports免费全文
  16. Intensity-modulated radiotherapy alone compared with intensity-modulated radiotherapy plus concurrent chemotherapy in intermediate-risk nasopharyngeal carcinoma : A prospective multicenter phase II trial.2024Strahlentherapie und Onkologie : Organ der Deutschen Rontgengesellschaft ... [et al]RCT
  17. Building Practical Risk Prediction Models for Nasopharyngeal Carcinoma Screening with Patient Graph Analysis and Machine Learning.2023Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology
  18. Apatinib combined with camrelizumab in the treatment of recurrent/metastatic nasopharyngeal carcinoma: a prospective multicenter phase II study.2023Frontiers in immunology免费全文
  19. Clinical Significance of Serum Iron Metabolism-Related Markers in Patients with Nasopharyngeal Carcinoma.2023ORL; journal for oto-rhino-laryngology and its related specialties
  20. RNA-binding domain 2 of nucleolin is important for the autophagy induction of curcumol in nasopharyngeal carcinoma cells.2023Phytomedicine : international journal of phytotherapy and phytopharmacology
  21. Aloe-emodin targets multiple signaling pathways by blocking ubiquitin-mediated degradation of DUSP1 in nasopharyngeal carcinoma cells.2023Phytotherapy research : PTR
  22. Hypofractionated radiotherapy compared with conventionally fractionated radiotherapy to treat initial distant metastases in nasopharyngeal carcinoma: A multicenter, prospective, randomized, phase II trial.2023Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and OncologyRCT
  23. MFSD4A inhibits the malignant progression of nasopharyngeal carcinoma by targeting EPHA2.2022Cell death & disease免费全文
  24. In silico analysis and experimental validation to exhibit anti-nasopharyngeal carcinoma effects of plumbagin, an anti-cancer compound.2022Journal of the science of food and agriculture
  25. Pathogenesis and Diagnostic Significance of EBV-miR-BARTs in Nasopharyngeal Carcinoma.2022Oxidative medicine and cellular longevity免费全文
  26. Study on the biological mechanism of urolithin a on nasopharyngeal carcinoma in vitro.2022Pharmaceutical biology免费全文
  27. Pentagalloylglucose suppresses the growth and migration of human nasopharyngeal cancer cells via the GSK3β/β-catenin pathway in vitro and in vivo.2022Phytomedicine : international journal of phytotherapy and phytopharmacology
  28. Nomogram for distant metastasis-free survival in patients with locoregionally advanced nasopharyngeal carcinoma.2022Strahlentherapie und Onkologie : Organ der Deutschen Rontgengesellschaft ... [et al]
  29. Curcumol inhibits EBV-positive Nasopharyngeal carcinoma migration and invasion by targeting nucleolin.2021Biochemical pharmacology
  30. Apatinib for the treatment of metastatic or locoregionally recurrent nasopharyngeal carcinoma after failure of chemotherapy: A multicenter, single-arm, prospective phase 2 study.2021Cancer
  31. Methylation-associated silencing of miR-9-1 promotes nasopharyngeal carcinoma progression and glycolysis via HK2.2021Cancer science免费全文
  32. Exosomes in nasopharyngeal carcinoma.2021Clinica chimica acta; international journal of clinical chemistry
  33. Optimization, Characterization and in vivo Evaluation of Paclitaxel-Loaded Folate-Conjugated Superparamagnetic Iron Oxide Nanoparticles.2021International journal of nanomedicine免费全文
  34. Impact of the weekday of the first intensity-modulated radiotherapy treatment on the survival outcomes of patients with nasopharyngeal carcinoma: A multicenter cohort study.2021Oral oncology
  35. Curcumol simultaneously induces both apoptosis and autophagy in human nasopharyngeal carcinoma cells.2021Phytotherapy research : PTR
它在 ClinicalTrials.gov 上的全部试验(任何状态)13
  1. Maintenance Treatment of Apatinib in Nasopharyngeal Carcinoma状态不明NCT03130270牵头方II期2017-01 启动
  2. Impacted Tooth Management and Osteoradionecrosis Risk in NPC即将招募NCT07764887研究中心不分期2026-08 启动
  3. Ivonescimab Combined With Chemoradiotherapy in High-Risk Locoregionally Advanced Nasopharyngeal Carcinoma即将招募NCT07064902研究中心II期2026-08 启动
  4. A Study of YL201 in Combination With Toripalimab and With or Without Cisplatin in Nasopharyngeal Carcinoma.正在招募NCT07258979研究中心I/II期2025-11 启动
  5. Effect of Immunonutrients on Oral Mucositis in Nasopharyngeal Carcinoma Patients After Chemoradiotherapy正在招募NCT05892354研究中心不分期2023-06 启动
  6. Concurrent and Adjuvant Nimotuzumab Combined With Induction Chemotherapy Plus Chemoradiation in Nasopharyngeal Carcinoma正在招募NCT05717790研究中心不分期2022-12 启动
  7. Induction Chemotherapy Followed by IMRT or Concurrent Chemoradiotherapy in Locoregionally Advanced Nasopharyngeal Carcinoma正在招募NCT05527470研究中心III期2022-11 启动
  8. Camrelizumab for the Treatment of Locally Advanced Nasopharyngeal Carcinoma状态不明NCT05097209研究中心II期2022-04 启动
  9. A Study of Penpulimab (AK105) in the First-line Treatment of Recurrent or Metastatic Nasopharyngeal Carcinoma进行中,不再招募NCT04974398研究中心III期2021-08 启动
  10. Apatinib Combined With PD-1 in the Treatment of Recurrent or Metastatic Nasopharyngeal Carcinoma已完成NCT04350190研究中心II期2021-01 启动
  11. Demethylated Drug in the Treatment of Nasopharyngeal Carcinoma状态不明NCT03701451研究中心I/II期2018-02 启动
  12. Adjuvant Treatment of Apatinib in Nasopharyngeal Carcinoma状态不明NCT03612219研究中心II期2018-07 启动
  13. ADjuVant Apatinib in Nasopharyngeal Carcinoma Patients With Residual Epstein-Barr Virus (EBV) DNA Following Radiotherapy已终止NCT02874651研究中心II期2016-10 启动
PubMed 以外找到的论文(未计入)5
  1. Adjuvant apatinib following concurrent chemoradiotherapy in high-risk nasopharyngeal carcinoma: A multicenter, prospective, phase 2 study.2025Journal of Clinical Oncology论文
  2. An Integrated Analysis of RNA Sequencing and Molecular Docking Reveal EIF2AK2, IFIT1, and STAT1 as Key Targets of EGCG in Nasopharyngeal Carcinoma2025Research Square预印本
  3. Hypofractionated radiotherapy compared with conventionally fractionated radiotherapy to treat initial distant metastases in nasopharyngeal carcinoma: A multicenter, prospective, randomized, phase II trial.2023Journal of Clinical Oncology会议摘要
  4. Icariside II targets in vitro MAPK and PI3K/Akt signaling in human nasopharyngeal carcinoma cells to induce apoptotic death and suppress proliferation2023Research Square预印本
  5. Abstract 5128: Identification and characterization of nasopharyngeal carcinoma prognostic subtypes based on a circRNA classifier: Implications of stratified treatment2022Cancer Research会议摘要

打开 PubMed 检索ClinicalTrials.gov

癌症

肝细胞癌

Hepatocellular carcinoma

2021–2025 年中国大陆作者发表的 14,765 篇肝细胞癌 PubMed 英文论文中,这家医院牵头了 66 篇,占 0.4%。

牵头论文
66
2021–2025 年
牵头试验
1
任何状态,ClinicalTrials.gov
牵头的开放试验
1
正在或即将招募
作为研究中心的开放试验
1
由其他机构牵头
每年牵头的论文数
2021: 101020212022: 111120222023: 111120232024: 151520242025: 18182025

桂林有 1 家医院列在肝细胞癌下全国有 192 家医院列在肝细胞癌下

这家医院参与的开放试验 2

依据 ClinicalTrials.gov 在 2026年11月8日 的登记,包括正在招募、即将招募和邀请入组。仅在中国临床试验注册中心(ChiCTR)登记的试验不在其中。能否参加由研究团队决定。

  1. 正在招募
    The Impact of Emotional Stress on Immunotherapy Outcomes in Liver Cancer Patients: A Multi-Cohort Study
    分期
    未注明
    开始
    2025-01
    登记号
    NCT07141056

    年龄 18 岁 至 未注明(登记的条件)

    牵头:桂林医学院附属医院;另有 1 家列出的医院为研究中心桂林、湛江

  2. 正在招募
    ABSK-011+BSC vs. Placebo+BSC in Previously Treated Advanced HCC With FGF19 Overexpression
    分期
    II期
    开始
    2025-06
    登记号
    NCT07327034

    年龄 18 岁 至 未注明(登记的条件)

    牵头方不是列出的医院;另有 39 家列出的医院为研究中心上海、北京、南京、南宁、南昌、南通、合肥、天津、广州、徐州、成都、杭州、桂林、武汉、沈阳、济南、福州、西安、赣州、郑州、重庆、银川、长春、长沙

在试验总页面查看

排列:先正在招募,再即将招募和邀请入组;同类按开始时间从新到旧。不是排名。

这些数字背后的记录
研究主题复发与预后影像、人工智能与早期发现免疫与靶向药物
论文中的科室普外/肝胆胰外科消化/肝病科影像/核医学科病理/检验科

这些论文过半是实验室或动物研究。

牵头的论文66
  1. Bimetallic Nanozyme Amplifier for Synergistic Ferroptosis-Cuproptosis and Metabolic Reprogramming to Reshape Immunosuppressive Tumor Microenvironment.2026Advanced science (Weinheim, Baden-Wurttemberg, Germany)免费全文
  2. Development of a nomogram for predicting microvascular invasion in patients with hepatocellular carcinoma.2025BMC cancer免费全文
  3. Exploring SLC25A42 as a Radiogenomic Marker from the Perioperative Stage to Chemotherapy in Hepatitis-Related Hepatocellular Carcinoma.2025Cancer biotherapy & radiopharmaceuticals
  4. USP7-DDX5-FASN axis drives fatty acid metabolism and supports hepatocellular carcinoma progression.2025Cellular signalling
  5. Diagnostic performance of LR-5 based on hypointensity on Gd-EOB-DTPA-enhanced MRI in the hepatobiliary phase for sHCC using LI-RADS v2018 criteria.2025Clinical radiology
  6. The PLANES model for unresectable hepatocellular carcinoma treated with transcatheter arterial chemoembolization plus lenvatinib and PD-1 inhibitors: a multicenter, retrospective study.2025Frontiers in immunology免费全文
  7. Case Report: Successful immune checkpoint inhibitor rechallenge after sintilimab-induced Guillain-Barré syndrome.2025Frontiers in immunology免费全文
  8. Integrated multi-omics analysis and machine learning refine molecular subtypes and clinical outcome for hepatocellular carcinoma.2025Hereditas免费全文
  9. NDUFAB1 promotes hepatocellular carcinoma progression by disrupting mitochondrial homeostasis and mitophagy pathway.2025International immunopharmacology
  10. Dihydroartemisinin alleviates diethylnitrosamine-induced hepatocarcinogenesis by targeting a novel MAZ/TRIM50 axis.2025International immunopharmacology
  11. MOF-Mediated Aloe-Emodin Delivery Enhances Hepatocellular Carcinoma Immunotherapy via Pyroptosis and Immunosuppressant Synergy.2025International journal of nanomedicine免费全文
  12. Hypericin Nanoparticles-Associated Photodynamic Therapy Modulates the Biological Behavior of Hepatocellular Carcinoma by SERPINE1.2025International journal of nanomedicine免费全文
  13. Casein kinase 1 family member CSNK1E can regulate proliferation and migration in hepatocellular carcinoma.2025Journal of cancer research and clinical oncology免费全文
  14. MAZ-mediated N6-methyladenosine modification of ZEB1 promotes hepatocellular carcinoma progression by regulating METTL3.2025Journal of translational medicine免费全文
  15. Alterations of Nutrient Elements in Hepatocellular Carcinoma Patients Treated with Atezolizumab-Bevacizumab.2025Nutrition and cancer
  16. Novel Strategies against Hepatocellular Carcinoma through Lipid Metabolism.2025Oncology research免费全文
  17. A clinical study exploring the prediction of microvascular invasion in hepatocellular carcinoma through the use of combined enhanced CT and MRI radiomics.2025PloS one免费全文
  18. EXOSC3 knockdown induces G1/S phase arrest to suppress hepatocellular carcinoma cell proliferation.2025Scientific reports免费全文
  19. Bioinformatics identification of shared signaling pathways and core targets linking Benzo[a]pyrene exposure to HCC progression.2025Toxicology
  20. Identification and validation of methylation-CpG prognostic signature for prognosis of hepatocellular carcinoma.2024Aging免费全文
  21. SNRPB promotes the progression of hepatocellular carcinoma via regulating cell cycle, oxidative stress, and ferroptosis.2024Aging免费全文
  22. Radiomics model based on contrast-enhanced computed tomography imaging for early recurrence monitoring after radical resection of AFP-negative hepatocellular carcinoma.2024BMC cancer免费全文
  23. Methylation-regulated tumor suppressor gene PDE7B promotes HCC invasion and metastasis through the PI3K/AKT signaling pathway.2024BMC cancer免费全文
  24. Deciphering the immunological and prognostic features of hepatocellular carcinoma through ADP-ribosylation-related genes analysis and identify potential therapeutic target ARFIP2.2024Cellular signalling
  25. The Combination of Gd-EOB-DTPA Enhanced T1 Mapping with Apparent Diffusion Coefficient could Improve the Diagnostic Efficacy of Hepatocellular Carcinoma Grading.2024Current medical imaging
  26. Role of Ubiquitin-specific Proteases in Hepatocellular Carcinoma Pathogenesis.2024Current topics in medicinal chemistry
  27. A Novel lncRNA lncRNA-4045 Promotes the Progression of Hepatocellular Carcinoma by Affecting the Expression of AKR1B10.2024Digestive diseases and sciences
  28. GCF2 mediates nicotine-induced cancer stemness and progression in hepatocellular carcinoma.2024Ecotoxicology and environmental safety
  29. Case report: Complete response after transcatheter arterial chemoembolization combined with donafenib plus tislelizumab therapy for hepatocellular carcinoma with main trunk portal vein tumor thrombus in a patient coinfected with HIV and HBV2024Frontiers in immunology免费全文
  30. REXO2 up-regulation is positively correlated with poor prognosis and tumor immune infiltration in hepatocellular carcinoma.2024International immunopharmacology
  31. Iron-Based Nanoplatforms Achieve Hepatocellular Carcinoma Regression Through a Cascade of Effects.2024International journal of nanomedicine免费全文
  32. Hepatic infarction occurred after 125I particle stent treatment for hepatocellular carcinoma with portal vein tumor thrombus: A case report.2024Journal of cancer research and clinical oncology免费全文
  33. A Network Meta-analysis of the Efficacy of Drug Therapy in First-line Treatment of Advanced Hepatocellular Carcinoma.2024Journal of gastrointestinal and liver diseases : JGLD
  34. The long-term efficacy and safety of apatinib are inferior to sorafenib in the first-line treatment of advanced hepatocellular carcinoma: A systematic review and meta-analysis.2024Medicine免费全文
  35. ZBTB34 is a hepatocellular carcinoma-associated protein with a monopartite nuclear localization signal.2023Aging免费全文
  36. Integrated network findings reveal ubiquitin-specific protease 44 overexpression suppresses tumorigenicity of liver cancer.2023Aging免费全文
  37. Prognostic Significance of ZP3 in Hepatocellular Carcinoma.2023Combinatorial chemistry & high throughput screening
  38. Prediction of early treatment response to the combination therapy of TACE plus lenvatinib and anti-PD-1 antibody immunotherapy for unresectable hepatocellular carcinoma: Multicenter retrospective study.2023Frontiers in immunology免费全文
  39. Equilibrative nucleoside transporter 3 promotes the progression of hepatocellular carcinoma by regulating the AKT/mTOR signaling pathway.2023International journal of biological macromolecules
  40. Aberrant expression of cuproptosis‑related gene LIPT1 is associated with metabolic dysregulation of fatty acid and prognosis in hepatocellular carcinoma.2023Journal of cancer research and clinical oncology免费全文
  41. Pulmonary interleukin 1 beta/serum amyloid A3 axis promotes lung metastasis of hepatocellular carcinoma by facilitating the pre-metastatic niche formation.2023Journal of experimental & clinical cancer research : CR免费全文
  42. The mechanism of LSM2 in the progression of live hepatocellular carcinoma was analyzed based on bioinformatics.2023Medical oncology (Northwood, London, England)
  43. Effectiveness and safety of anlotinib with or without S-1 in the treatment of patients with advanced hepatocellular carcinoma in a Chinese population: a prospective, phase 2 study.2023Radiology and oncologyRCT免费全文
  44. Nomogram for predicting severe abdominal pain after initial conventional transarterial chemoembolisation for hepatocellular carcinoma: a retrospective study.2023Scientific reports免费全文
  45. Radiomics model based on contrast-enhanced computed tomography to predict early recurrence in patients with hepatocellular carcinoma after radical resection.2023World journal of gastroenterology免费全文
  46. Clinical Significance of TUBGCP4 Expression in Hepatocellular Carcinoma.2022Analytical cellular pathology (Amsterdam)免费全文
  47. Prognostic significance and immune characteristics of CMTM4 in hepatocellular carcinoma.2022BMC cancer免费全文
  48. S1PR1 induces metabolic reprogramming of ceramide in vascular endothelial cells, affecting hepatocellular carcinoma angiogenesis and progression.2022Cell death & disease免费全文
  49. Exosomal miR-628-5p from M1 polarized macrophages hinders m6A modification of circFUT8 to suppress hepatocellular carcinoma progression.2022Cellular & molecular biology letters免费全文
  50. Anti-hepatoma Effect of DC2.4 Cells Transfected with Tumor-Associated Antigen Cdc25C In Vitro.2022Current medical science
  51. G Protein-Coupled Receptor Kinase 4 Is a Novel Prognostic Factor in Hepatocellular Carcinoma.2022Disease markers免费全文
  52. Hepatocyte-targeting and tumor microenvironment-responsive liposomes for enhanced anti-hepatocarcinoma efficacy.2022Drug delivery免费全文
  53. Hypoxia-induced LncRNA DACT3-AS1 upregulates PKM2 to promote metastasis in hepatocellular carcinoma through the HDAC2/FOXA3 pathway.2022Experimental & molecular medicine免费全文
  54. hsa-miR-9-5p-Mediated TSPAN9 Downregulation Is Positively Related to Both Poor Hepatocellular Carcinoma Prognosis and the Tumor Immune Infiltration.2022Journal of immunology research免费全文
  55. Circ_0036412 affects the proliferation and cell cycle of hepatocellular carcinoma via hedgehog signaling pathway.2022Journal of translational medicine免费全文
  56. Preoperative contrast-enhanced computed tomography-based radiomics model for overall survival prediction in hepatocellular carcinoma.2022World journal of gastroenterologyRCT免费全文
  57. Clinical characterization and therapeutic targets of vitamin A in patients with hepatocholangiocarcinoma and coronavirus disease.2021Aging免费全文
  58. Predictive potential of Nomogram based on GMWG for patients with hepatocellular carcinoma after radical resection.2021BMC cancer免费全文
  59. AGLR is a novel index for the prognosis of hepatocellular carcinoma patients: a retrospective study.2021BMC surgeryRCT免费全文
  60. RNA sequencing identifies two novel liver-specific long noncoding RNAs with potential diagnostic value in hepatocellular carcinoma.2021Biomarkers in medicine
  61. A new model based on gamma-glutamyl transpeptidase to platelet ratio (GPR) predicts prognostic outcome after curative resection of solitary hepatocellular carcinoma.2021Clinics and research in hepatology and gastroenterology
  62. CircRNA profiling identifies circRNF180 as a tumor suppressor in hepatocellular carcinoma.2021Epigenomics
  63. Lnc-ATG9B-4 aggravates progress of hepatocellular carcinoma through cell proliferation and migration by upregulating CDK5.2021Experimental biology and medicine (Maywood, N.J.)免费全文
  64. Exosomes synergized with PIONs@E6 enhance their immunity against hepatocellular carcinoma via promoting M1 macrophages polarization.2021International immunopharmacology
  65. Deciphering the effects of PYCR1 on cell function and its associated mechanism in hepatocellular carcinoma.2021International journal of biological sciences免费全文
  66. Anti-hepatitis B virus activity and hepatoprotective effect of des(rhamnosyl) verbascoside from Lindernia ruellioides in vitro.2021Phytotherapy research : PTR
中文论文(未计入)2
  1. [VIPR1 promoter methylation promotes transcription factor AP-2α binding to inhibit VIPR1 expression and promote hepatocellular carcinoma cell growth in vitro].2022Nan fang yi ke da xue xue bao = Journal of Southern Medical University免费全文
  2. [miR-152 inhibits the epithelial-mesenchymal transition and renin-angiotensin system of human hepatocellular carcinoma cells by down-regulating AGTR1].2022Xi bao yu fen zi mian yi xue za zhi = Chinese journal of cellular and molecular immunology
它在 ClinicalTrials.gov 上的全部试验(任何状态)3
  1. The Impact of Emotional Stress on Immunotherapy Outcomes in Liver Cancer Patients: A Multi-Cohort Study正在招募NCT07141056牵头方2025-01 启动
  2. ABSK-011+BSC vs. Placebo+BSC in Previously Treated Advanced HCC With FGF19 Overexpression正在招募NCT07327034研究中心II期2025-06 启动
  3. The Phase III Study of Icaritin Versus HUACHANSU PIAN in Hepatocellular Carcinoma Subjects状态不明NCT03236636研究中心III期2017-09 启动

打开 PubMed 检索ClinicalTrials.gov

癌症

脊索瘤

Chordoma

2021–2025 年中国大陆作者发表的 105 篇脊索瘤 PubMed 英文论文中,这家医院牵头了 1 篇,占 0.9%。

牵头论文
1
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头
每年牵头的论文数
2021: 0020212022: 0020222023: 0020232024: 1120242025: 002025

桂林有 1 家医院列在脊索瘤下全国有 88 家医院列在脊索瘤下

截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的脊索瘤开放试验。

这些数字背后的记录
论文中的科室神经外科

打开 PubMed 检索ClinicalTrials.gov

癌症

骨肉瘤

Osteosarcoma

2021–2025 年中国大陆作者发表的 2,257 篇骨肉瘤 PubMed 英文论文中,这家医院牵头了 3 篇,占 0.1%。

牵头论文
3
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头
每年牵头的论文数
2021: 2220212022: 0020222023: 1120232024: 0020242025: 002025

桂林有 3 家医院列在骨肉瘤下全国有 742 家医院列在骨肉瘤下

截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的骨肉瘤开放试验。

这些数字背后的记录
论文中的科室耳鼻喉/头颈外科消化/肝病科肿瘤内科
牵头的论文3
  1. Cracking the code: Deciphering the role of the tumor microenvironment in osteosarcoma metastasis.2023International immunopharmacology
  2. Anti-neoplastic characteristics and potential targets of calycosin against bisphenol A-related osteosarcoma: bioinformatics analysis.2021Bioengineered
  3. microRNA-377-3p inhibits osteosarcoma progression by targeting CUL1 and regulating Wnt/β-catenin signaling pathway.2021Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico
中文论文(未计入)1
  1. [Atypical extraosseous Ewing's sarcoma of sinonasal cranial base: a case report].2024Zhonghua er bi yan hou tou jing wai ke za zhi = Chinese journal of otorhinolaryngology head and neck surgery
早期论文(2016–2020 年)2
  1. Expression and significance of Annexin A3 in the osteosarcoma cell lines HOS and U2OS.2019Molecular medicine reports
  2. Celastrol increases osteosarcoma cell lysis by γδ T cells through up-regulation of death receptors.2016Oncotarget

打开 PubMed 检索ClinicalTrials.gov

癌症

神经母细胞瘤

Neuroblastoma

2021–2025 年中国大陆作者发表的 1,132 篇神经母细胞瘤 PubMed 英文论文中,这家医院牵头了 3 篇,占 0.3%。

牵头论文
3
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头
每年牵头的论文数
2021: 0020212022: 3320222023: 0020232024: 0020242025: 002025

桂林有 1 家医院列在神经母细胞瘤下全国有 352 家医院列在神经母细胞瘤下

截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的神经母细胞瘤开放试验。

这些数字背后的记录
论文中的科室神经外科

打开 PubMed 检索ClinicalTrials.gov

癌症

尤文肉瘤

Ewing sarcoma

2021–2025 年没有牵头尤文肉瘤的 PubMed 英文论文。下方可查看与这家医院关联的研究记录。

牵头论文
0
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头

桂林有 1 家医院列在尤文肉瘤下全国有 139 家医院列在尤文肉瘤下

截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的尤文肉瘤开放试验。

这些数字背后的记录
论文中的科室耳鼻喉/头颈外科
中文论文(未计入)1
  1. [Atypical extraosseous Ewing's sarcoma of sinonasal cranial base: a case report].2024Zhonghua er bi yan hou tou jing wai ke za zhi = Chinese journal of otorhinolaryngology head and neck surgery

打开 PubMed 检索ClinicalTrials.gov

血液疾病

多发性骨髓瘤

Multiple myeloma

2021–2025 年中国大陆作者发表的 1,676 篇多发性骨髓瘤 PubMed 英文论文中,这家医院牵头了 3 篇,占 0.2%。

牵头论文
3
2021–2025 年
牵头试验
1
任何状态,ClinicalTrials.gov
牵头的开放试验
1
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头
每年牵头的论文数
2021: 0020212022: 1120222023: 1120232024: 0020242025: 112025

桂林有 1 家医院列在多发性骨髓瘤下全国有 178 家医院列在多发性骨髓瘤下

这家医院参与的开放试验 1

依据 ClinicalTrials.gov 在 2026年11月8日 的登记,包括正在招募、即将招募和邀请入组。仅在中国临床试验注册中心(ChiCTR)登记的试验不在其中。能否参加由研究团队决定。

  1. 正在招募
    CD38 Targeted -PET/ CT for Multiple Myeloma
    分期
    不分期
    开始
    2026-07
    登记号
    NCT07782944

    年龄 18 岁 至 未注明(登记的条件)

    牵头:桂林医学院附属医院桂林

在试验总页面查看

排列:先正在招募,再即将招募和邀请入组;同类按开始时间从新到旧。不是排名。

这些数字背后的记录
研究主题诊断、微小残留病与危险分层
论文中的科室病理/检验科

打开 PubMed 检索ClinicalTrials.gov

血液疾病

β 地中海贫血

Beta thalassaemia

2021–2025 年中国大陆作者发表的 312 篇β 地中海贫血 PubMed 英文论文中,这家医院牵头了 3 篇,占 1.0%。

牵头论文
3
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头
每年牵头的论文数
2021: 0020212022: 1120222023: 0020232024: 1120242025: 112025

桂林有 2 家医院列在β 地中海贫血下全国有 157 家医院列在β 地中海贫血下

截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的β 地中海贫血开放试验。

这些数字背后的记录

打开 PubMed 检索ClinicalTrials.gov

其他疾病

肝包虫病

Hepatic echinococcosis

2021–2025 年中国大陆作者发表的 152 篇肝包虫病 PubMed 英文论文中,这家医院牵头了 2 篇,占 1.3%。

牵头论文
2
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头
每年牵头的论文数
2021: 1120212022: 0020222023: 0020232024: 0020242025: 112025

桂林有 1 家医院列在肝包虫病下全国有 49 家医院列在肝包虫病下

截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的肝包虫病开放试验。

这些数字背后的记录

打开 PubMed 检索ClinicalTrials.gov

其他疾病

特发性肺纤维化

Idiopathic pulmonary fibrosis

2021–2025 年中国大陆作者发表的 989 篇特发性肺纤维化 PubMed 英文论文中,这家医院牵头了 1 篇,占 0.1%。

牵头论文
1
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头
每年牵头的论文数
2021: 0020212022: 0020222023: 1120232024: 0020242025: 002025

桂林有 1 家医院列在特发性肺纤维化下全国有 333 家医院列在特发性肺纤维化下

截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的特发性肺纤维化开放试验。

这些数字背后的记录
论文中的科室影像/核医学科

打开 PubMed 检索ClinicalTrials.gov

其他疾病

白塞病

Behçet disease

2021–2025 年没有牵头白塞病的 PubMed 英文论文。下方可查看与这家医院关联的研究记录。

牵头论文
0
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
1
由其他机构牵头

桂林有 1 家医院列在白塞病下全国有 149 家医院列在白塞病下

这家医院参与的开放试验 1

依据 ClinicalTrials.gov 在 2026年11月13日 的登记,包括正在招募、即将招募和邀请入组。仅在中国临床试验注册中心(ChiCTR)登记的试验不在其中。能否参加由研究团队决定。

  1. 正在招募
    A Study of Efficacy and Safety of Hemay005 Tablets in Patients With Behçet's Disease
    分期
    III期
    开始
    2023-11
    登记号
    NCT06145893

    年龄 18 岁 至 75 岁(登记的条件)

    牵头方不是列出的医院;另有 20 家列出的医院为研究中心上海、临沂、北京、南昌、厦门、太原、广州、徐州、杭州、桂林、深圳、温州、石家庄、苏州

在试验总页面查看

排列:先正在招募,再即将招募和邀请入组;同类按开始时间从新到旧。不是排名。

这些数字背后的记录
它在 ClinicalTrials.gov 上的全部试验(任何状态)1
  1. A Study of Efficacy and Safety of Hemay005 Tablets in Patients With Behçet's Disease正在招募NCT06145893研究中心III期2023-11 启动

打开 PubMed 检索ClinicalTrials.gov

其他疾病

IgA 肾病

IgA nephropathy

2021–2025 年中国大陆作者发表的 736 篇IgA 肾病 PubMed 英文论文中,这家医院牵头了 1 篇,占 0.1%。

牵头论文
1
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头
每年牵头的论文数
2021: 0020212022: 0020222023: 0020232024: 0020242025: 112025

桂林有 1 家医院列在IgA 肾病下全国有 346 家医院列在IgA 肾病下

截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的IgA 肾病开放试验。

这些数字背后的记录
论文中的科室肾内科
牵头的论文1
  1. Impact of crescents on the immunosuppression treatment of IgA nephropathy.2025Renal failure
中文论文(未计入)1
  1. Characteristics of disease distribution for the 1 370 renal biopsy cases in two hospitals from Guilin and Jining.2021Zhong nan da xue xue bao. Yi xue ban = Journal of Central South University. Medical sciences
它在 ClinicalTrials.gov 上的全部试验(任何状态)2
  1. A Study of Telitacicept for IgA Nephropathy (TELIGAN)进行中,不再招募NCT05799287研究中心III期2023-04 启动
  2. Efficacy and Safety of Abelmoschus Manihot for IgA Nephropathy状态不明NCT02231125研究中心IV期2014-09 启动

打开 PubMed 检索ClinicalTrials.gov

联系这家医院

出示给工作人员或司机的院名卡

桂林医学院附属医院

Affiliated Hospital of Guilin Medical University

桂林

大医院往往有多个院区,出发前请先向医院确认院区。

中英对照的咨询信

填写方括号中的内容后,通过医院国际医疗部或官网上的联系方式发送。在这里输入的内容不会离开您的设备。

医院通常需要的资料

  • 主治医生近期的病情总结或信件
  • 病理报告
  • 影像检查(CT、MRI、PET)及报告,尽量附影像文件
  • 已接受的治疗及时间
  • 目前用药

下一步建议

与主治医生沟通可将本页分享给主治医生,一同评估该团队的研究方向是否相关。
确认团队现状论文发表通常滞后数月,医生也可能调动。请在医院官网查询相关科室。
直接联系医院请通过医院官方公布的渠道联系。医院不向我们支付任何费用;是否接诊由医院决定。

这些数字从哪里来

论文

2021–2025 年 PubMed 英文论文中,第一作者或最后作者的第一单位是这家医院的论文。 定义

试验

ClinicalTrials.gov 上列出这家医院为牵头方或研究中心的记录,截至 2026年11月8日。

编号与其他名称

ROR Wikidata
Guilin Medical University; Second Affiliated Hospital of Guilin Medical University; Guilin Medical University Affiliated Hospital; Affiliated Hospital of Guilin Medical College; First Affiliated Hospital of Guilin Medical University; College of International Education of Guilin Medical University

提出更正下载数据